Structure-Based Identification of Organoruthenium Compounds as Nanomolar Antagonists of Cannabinoid Receptors

被引:3
|
作者
Wang, Qing [1 ,2 ]
Fu, Xuegang [1 ]
Yan, Yuting [1 ]
Liu, Tao [1 ,2 ]
Xie, Yuting [2 ]
Song, Xiaoqing [1 ]
Zhou, Yu [2 ]
Xu, Min [2 ]
Wang, Ping [2 ]
Fu, Peng [1 ]
Huang, Jianhui [1 ]
Huang, Niu [2 ,3 ]
机构
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China
[2] Natl Inst Biol Sci, Beijing 102206, Peoples R China
[3] Tsinghua Univ, Tsinghua Inst Multidisciplinary Biomed Res, Beijing 102206, Peoples R China
基金
中国国家自然科学基金;
关键词
STRUCTURE-BASED DISCOVERY; HALF-SANDWICH COMPLEXES; FORCE-FIELD; REVERSE DOCKING; CHEMICAL SPACE; KINASE; LIGAND; INHIBITORS; THERAPY; TARGET;
D O I
10.1021/acs.jcim.3c01282
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Metal complexes exhibit a diverse range of coordination geometries, representing novel privileged scaffolds with convenient click types of preparation inaccessible for typical carbon-centered organic compounds. Herein, we explored the opportunity to identify biologically active organometallic complexes by reverse docking of a rigid, minimum-size octahedral organoruthenium scaffold against thousands of protein-binding pockets. Interestingly, cannabinoid receptor type 1 (CB1) was identified based on the docking scores and the degree of overlap between the docked organoruthenium scaffold and the hydrophobic scaffold of the cocrystallized ligand. Further structure-based optimization led to the discovery of organoruthenium complexes with nanomolar binding affinities and high selectivity toward CB2. Our work indicates that octahedral organoruthenium scaffolds may be advantageous for targeting the large and hydrophobic binding pockets and that the reverse docking approach may facilitate the discovery of novel privileged scaffolds, such as organometallic complexes, for exploring chemical space in lead discovery.
引用
收藏
页码:761 / 774
页数:14
相关论文
共 50 条
  • [21] LigTMap: ligand and structure-based target identification and activity prediction for small molecular compounds
    Shaikh, Faraz
    Tai, Hio Kuan
    Desai, Nirali
    Siu, Shirley W. I.
    JOURNAL OF CHEMINFORMATICS, 2021, 13 (01)
  • [22] Discovery of novel GPVI receptor antagonists by structure-based repurposing
    Coxon, C. H.
    Taylor, L.
    Vasudevan, S. R.
    Jones, C., I
    Churchill, G. C.
    Campbell, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 106 - 106
  • [23] Discovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
    Taylor, Lewis
    Vasudevan, Sridhar R.
    Jones, Chris I.
    Gibbins, Jonathan M.
    Churchill, Grant C.
    Campbell, R. Duncan
    Coxon, Carmen H.
    PLOS ONE, 2014, 9 (06):
  • [24] Structure-Based Design of Biologically Active Compounds
    Gemma, Sandra
    MOLECULES, 2020, 25 (14):
  • [25] Structure-based screening for discovery of sweet compounds
    Ben Shoshan-Galeczki, Yaron
    Niv, Masha Y.
    FOOD CHEMISTRY, 2020, 315
  • [26] Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D
    Kick, EK
    Roe, DC
    Skillman, AG
    Liu, GC
    Ewing, TJA
    Sun, YX
    Kuntz, ID
    Ellman, JA
    CHEMISTRY & BIOLOGY, 1997, 4 (04): : 297 - 307
  • [27] G Protein Coupled Receptors and Structure-Based Advances
    Kontoyianni, Maria
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (13) : 1489 - 1505
  • [28] De novo structure-based design of anion receptors
    Hay, Benjamin P.
    CHEMICAL SOCIETY REVIEWS, 2010, 39 (10) : 3700 - 3708
  • [29] Structure-based drug design for nuclear hormone receptors
    Krystek, SR
    Hamann, LG
    Salvati, ME
    Balog, A
    Hunt, J
    Li, J
    Manfredi, M
    Martinez, R
    Nayeem, A
    Nirsch, A
    Pickering, D
    Schnur, D
    Shan, WF
    Sun, CQ
    Wei, D
    Zhu, H
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U1294 - U1294
  • [30] Structure-based, rational design of T cell receptors
    Zoete, V.
    Irving, M.
    Ferber, M.
    Cuendet, M. A.
    Michielin, O.
    FRONTIERS IN IMMUNOLOGY, 2013, 4